Addressing Concerns for Successful Implementation of National Health Insurance in South Africa

By HEOR Staff Writer

May 10, 2023

Addressing Concerns for Successful Implementation of National Health Insurance in South Africa: Perspectives from Policymakers and the Role of Pharmacists in Primary Healthcare Re-engineering

In this study, policymakers in South Africa were interviewed to gain insights into their perspectives on the implementation of National Health Insurance (NHI) and the role of pharmacists in primary healthcare (PHC) re-engineering.

The study identified several concerns that could compromise the efficient functionality of NHI and attaining universal healthcare (UHC). These concerns included the need for appropriate governance and regulatory mechanisms, the complexity of issues experienced at local levels of care, the involvement of private healthcare providers and the lack of reimbursement mechanisms, the need for stakeholder engagement and communication, and the underutilization of pharmacists in the healthcare system. The study highlights the importance of proactive and positive engagement with key role-players to address these concerns and ensure the successful implementation of NHI and PHC re-engineering in South Africa.

Reference url

Recent Posts

Biopharma Ecosystem Competitiveness: Post-COVID Challenges and Opportunities

By João L. Carapinha

February 20, 2026

Biopharma Ecosystem Competitiveness in Global Race A new EFPIA analysis compares bioph...
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation

By João L. Carapinha

February 19, 2026

MFN Policy Effectiveness in Countering Freeloading Claims The MFN policy effectiveness is evident in the coalition letter dated February 12, 2026, which opposes codifying Most-Favored-Nation (MFN) prescription drug pricing b...
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implications for Alzheimer&...

By HEOR Staff Writer

February 18, 2026

Dutch Health Insurance Rejects Lecanemab Coverage Zorginstituut Nederland's advisory letter dated 13 February 2026 recommends against including lecanemab (Leqembi®) in the Dutch basic health insurance package, marking a key lecanema...